Black Diamond Therapeutics (BDTX) Share-based Compensation: 2018-2024
Historic Share-based Compensation for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to $10.6 million.
- Black Diamond Therapeutics' Share-based Compensation rose 36.68% to $3.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $14.0 million, marking a year-over-year increase of 80.77%. This contributed to the annual value of $10.6 million for FY2024, which is 10.65% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Share-based Compensation of $10.6 million as of FY2024, which was up 10.65% from $9.6 million recorded in FY2023.
- Black Diamond Therapeutics' 5-year Share-based Compensation high stood at $14.0 million for FY2021, and its period low was $7.8 million during FY2020.
- Moreover, its 3-year median value for Share-based Compensation was $10.6 million (2024), whereas its average is $10.8 million.
- In the last 5 years, Black Diamond Therapeutics' Share-based Compensation surged by 113.15% in 2020 and then dropped by 21.26% in 2023.
- Yearly analysis of 5 years shows Black Diamond Therapeutics' Share-based Compensation stood at $7.8 million in 2020, then spiked by 80.77% to $14.0 million in 2021, then fell by 13.11% to $12.2 million in 2022, then declined by 21.26% to $9.6 million in 2023, then rose by 10.65% to $10.6 million in 2024.